Scarica l'app Stockscreener
16.20
2.29%
-0.38
Dopo l'orario di chiusura:
16.19
-0.010
-0.06%
Precedente Chiudi:
$16.58
Aprire:
$16.57
Volume 24 ore:
424.52K
Relative Volume:
1.10
Capitalizzazione di mercato:
$5.74B
Reddito:
$5.10B
Utile/perdita netta:
$-352.00M
Rapporto P/E:
-15.90
EPS:
-1.0189
Flusso di cassa netto:
$-66.14M
1 W Prestazione:
-5.04%
1M Prestazione:
-4.87%
6M Prestazione:
+6.65%
1 anno Prestazione:
+6.65%
Intervallo 1D:
$16.16
$16.75
Intervallo di 1 settimana:
$16.16
$17.68
Portata 52W:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Nome
Bausch Lomb Corp
Settore
Industria
Telefono
908-541-5456
Indirizzo
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.20 | 5.74B | 5.10B | -352.00M | -66.14M | -1.0189 |
|
ISRG
Intuitive Surgical Inc
|
472.16 | 167.68B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
159.36 | 45.33B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
77.32 | 37.69B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
41.46 | 33.65B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
230.84 | 33.63B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Neutral |
| 2025-05-02 | Reiterato | H.C. Wainwright | Buy |
| 2025-03-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Iniziato | Raymond James | Outperform |
| 2024-05-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Iniziato | Stifel | Hold |
| 2023-10-03 | Ripresa | Evercore ISI | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Iniziato | Needham | Hold |
| 2022-12-21 | Iniziato | Barclays | Equal Weight |
| 2022-09-12 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-06-24 | Iniziato | Evercore ISI | Outperform |
| 2022-06-06 | Iniziato | Citigroup | Buy |
| 2022-05-31 | Iniziato | Deutsche Bank | Hold |
| 2022-05-31 | Iniziato | Goldman | Neutral |
| 2022-05-31 | Iniziato | Guggenheim | Buy |
| 2022-05-31 | Iniziato | JP Morgan | Neutral |
| 2022-05-31 | Iniziato | Jefferies | Buy |
| 2022-05-31 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Iniziato | Wells Fargo | Overweight |
| 2022-05-11 | Iniziato | Cowen | Outperform |
Mostra tutto
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch And Lomb (NYSE:BLCO) Glaucoma Moves Catch Market Eyes Nyse Composite Today - Kalkine Media
Bausch & Lomb (NYSE: BLCO) CFO buys 4,000 shares, gets 4,000 RSUs - Stock Titan
Bausch & Lomb (BLCO) CEO buys 14,700 shares and receives matching RSUs - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Inside Bausch + Lomb’s glaucoma webinar on new treatments - Stock Titan
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update - Yahoo Finance
Short Covering: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Levels & Fast Moving Market Watchlists - baoquankhu1.vn
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know - Finviz
Insider Buying: Ross Thomas W. Sr. Acquires Shares in Bausch & L - GuruFocus
Director adds BLCO stake with 4,500-share buy and 4,500 RSUs grant - Stock Titan
Potential Bausch + Lomb Separation Reframes Bausch Health - simplywall.st
Insider Buying: Eduardo Alfonso Acquires Shares of Bausch & Lomb Corp (BLCO) - GuruFocus
[Form 4] Bausch & Lomb Corp Insider Trading Activity - Stock Titan
Bausch & Lomb (NYSE: BLCO) director buys shares, gets RSUs - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Bausch & Lomb (BLCO) officer has shares withheld for RSU tax - Stock Titan
Tax-withholding share moves by Bausch & Lomb (NYSE: BLCO) executive - Stock Titan
Bausch & Lomb (BLCO) EVP uses share withholding to cover tax on RSU vesting - Stock Titan
Bausch & Lomb (BLCO) EVP uses shares for tax withholding on RSU vesting - Stock Titan
CFO tax share withholding at Bausch & Lomb (BLCO) after RSU vesting - Stock Titan
Bausch & Lomb (BLCO) CEO uses common shares to cover RSU tax - Stock Titan
Bausch & Lomb (BLCO) SVP awarded 18,253 restricted share units in Form 4 - Stock Titan
Executive at Bausch & Lomb (NYSE: BLCO) granted 32,710 restricted share units - Stock Titan
Bausch & Lomb (NYSE: BLCO) EVP awarded 35,046 restricted share units - Stock Titan
327,102-share RSU award to Bausch & Lomb (BLCO) CEO Brent Saunders - Stock Titan
Bausch + Lomb Corp. Hits New 52-Week High at $18.91 - Markets Mojo
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth - Insider Monkey
Bausch + Lomb stock hits 52-week high at $18.86 - Investing.com Australia
Bausch + Lomb stock hits 52-week high at $18.86 By Investing.com - Investing.com Canada
Bausch & Lomb (BLCO) CEO uses 65,444 shares to cover tax withholding - Stock Titan
Is Expert Backing Of LUMIFY’s Safety Profile Quietly Shaping Bausch + Lomb’s Consumer Strategy (BLCO)? - simplywall.st
5 Revealing Analyst Questions From Bausch + Lomb's Q4 Earnings Call - Finviz
Director Steven Collis adds BLCO stake with 15,000-share buy and RSU grant - Stock Titan
Director boosts Bausch & Lomb (BLCO) stake with share buy and matching RSUs - Stock Titan
Is It Time To Reassess Bausch + Lomb (BLCO) After Its Recent Share Price Strength? - Yahoo Finance
H.C. Wainwright raises Bausch & Lomb stock price target to $20 - Investing.com South Africa
H.C. Wainwright raises Bausch & Lomb stock price target to $20 By Investing.com - Investing.com Canada
HC Wainwright Comments on Bausch + Lomb Q1 Earnings - MarketBeat
Digital lifestyles are turning eyes red – and one drop stands out - Stock Titan
Adding B Vitamins To AREDS Has Bausch + Lomb Seeing Consumer Health Sales Boost Ahead - Citeline News & Insights
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook - Insider Monkey
Director Karen Ling adds Bausch & Lomb (BLCO) shares and gets 4,000 RSUs - Stock Titan
Director receives 5,255 RSUs at Bausch & Lomb (NYSE: BLCO) - Stock Titan
Bausch & Lomb (BLCO) awards 5,255 RSUs to director - Stock Titan
Director at Bausch & Lomb (BLCO) receives 1,451 restricted share units - Stock Titan
Director John Paulson granted 1,239 Bausch & Lomb (BLCO) restricted share units - Stock Titan
Bausch Lomb Corp Azioni (BLCO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):